Breaking tolerance to thyroid antigens: Changing concepts in thyroid autoimmunity

Endocrine Reviews

Volumn 35, Issue 1, 2014, Pages 59-105

  McLachlan, Sandra M ^a   Rapoport, Basil ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTITHYROID AGENT; AUTOANTIGEN; CD40 ANTIGEN; CROSS REACTING ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; INTERLEUKIN 2 RECEPTOR ALPHA; IODIDE; IODINE; LIOTHYRONINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; POLYCYCLIC AROMATIC HYDROCARBON; SELENIUM; SODIUM IODIDE SYMPORTER; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; THYROGLOBULIN; THYROID ANTIBODY; THYROID ANTIGEN; THYROID EXTRACT; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; THYROXINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ADAPTIVE IMMUNITY; ALTERNATIVE RNA SPLICING; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIVIRAL THERAPY; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL INFECTION; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELLULAR IMMUNITY; CROSS REACTION; DENDRITIC CELL; DIETARY INTAKE; DOWN SYNDROME; ENDOCRINE OPHTHALMOPATHY; ENVIRONMENTAL FACTOR; FREE THYROXINE INDEX; GENE MUTATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; GLYCOSYLATION; GRAVES DISEASE; HAPLOTYPE; HASHIMOTO DISEASE; HELPER CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HEPATITIS C; HINGE REGION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROCHIMERISM; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; RADIATION; RADIOACTIVE WASTE; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; THYMECTOMY; THYROID CANCER; THYROID FUNCTION; THYROID HYPERPLASIA; THYROIDITIS; VIRUS INFECTION; WHOLE BODY RADIATION;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; RECEPTORS, THYROTROPIN; T-LYMPHOCYTES; THYROID GLAND; THYROID HORMONES;

EID: 84893564439     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2013-1055     Document Type: Review

References (407)

1. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
2. Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. 2009;32:231-239.
3. NyeL, Pontes de Carvalho LC, Roitt IM. Restrictions in the response to autologous thyroglobulin in the human. Clin Exp Immunol. 1980;41:252-263.
4. Sundick RS, Herdegen DM, Brown TR, Bagchi N. The incorporation of dietary iodine into thyroglobulin increases its immunogenicity. Endocrinology. 1987;120: 2078-2084.
5. Champion BR, Page KR, Parish N, et al. Identification of a thyroxine-containing self-epitope of thyroglobulin which triggers thyroid autoreactive T cells. J Exp Med. 1991;174: 363-370.
6. SabooriAM,RoseNR,Bresler HS, Vladut-TalorM,Burek CL. Iodination of human thyroglobulin (Tg) alters its immunoreactivity. I. Iodination alters multiple epitopes of human Tg. Clin Exp Immunol. 1998;113:297-302.
7. Grennan Jones F, Wolstenholme A, Fowler S, et al. Highlevel expression of recombinant immunoreactive thyroid peroxidase in the High Five insect cell line. J Mol Endocrinol. 1996;17:165-174.
8. Guo J, McLachlan SM, Hutchison S, Rapoport B. The greater glycan content of recombinant human thyroid peroxidase of mammalian than of insect cell origin facilitates purification to homogeneity of enzymatically protein remaining soluble at high concentration. Endocrinology. 1998;139:999-1005.
9. Le Fourn V, Ferrand M, Franc JL. Endoproteolytic cleavage ofhumanthyroperoxidase: role of the propeptide in the protein folding process. J Biol Chem. 2005;280:4568-4577.
10. McLachlan SM, Rapoport B. Thyroid peroxidase as an autoantigen. Thyroid. 2007;17:939-948.
11. Rapoport B, McLachlan SM. The thyrotropin receptor in Graves' disease. Thyroid. 2007;17:911-922.
12. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458-460.
13. Raspé E, Costagliola S, Ruf J, Mariotti S, Dumont JE, Ludgate M. Identification of the thyroid Na+/I+ cotransporter as a potential autoantigen in thyroid autoimmune disease. Eur J Endocrinol. 1995;132:399-405.
14. Ajjan RA, Kemp EH, Waterman EA, et al. Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease. J Clin Endocrinol Metab. 2000;85:2020-2027.
15. Seissler J, Wagner S, Schott M, et al. Low frequency of autoantibodies to the human Na(+)/I(+) symporter in patients with autoimmune thyroid disease. J Clin Endocrinol Metab. 2000;85:4630-4634.
16. Heufelder AE, Joba W, Morgenthaler NG. Autoimmunity involving the human sodium/iodide symporter: fact or fiction? Exp Clin Endocrinol Diabetes. 2001;109:35-40.
17. Czarnocka B. Thyroperoxidase, thyroglobulin, Na(+)/ I(+) symporter, pendrin in thyroid autoimmunity. Front Biosci (Landmark Ed). 2011;16:783-802.
18. Kemp EH, Sandhu HK, Watson PF, Weetman AP. Low frequency of pendrin autoantibodies detected using a radioligand binding assay in patients with autoimmune thyroid disease. J Clin Endocrinol Metab. 2013;98:E309-E313.
19. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170:6348-6354.
20. Smith TJ. Is IGF-I receptor a target for autoantibody generation in Graves' disease? J Clin Endocrinol Metab. 2013; 98:515-518.
21. Varewijck AJ, Boelen A, Lamberts SW, et al. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2013;98:769-776.
22. Minich WB, Dehina N, Welsink T, et al. Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab. 2013;98:752-760.
23. ZakarijaM,McKenzie JM, Eidson MS. Transient neonatal hypothyroidism: characterization of maternal antibodies to the thyrotropin receptor. J Clin Endocrinol Metab. 1990;70:1239-1246.
24. Flynn JC, Gilbert JA, Meroueh C, et al. Chronic exposure in vivo to thyrotropin receptor stimulating monoclonal antibodies sustains high thyroxine levels and thyroid hyperplasia in thyroid autoimmunity-prone HLA-DRB1*0301 transgenic mice. Immunology. 2007;122:261-267.
25. Misharin AV, Rapoport B, McLachlan SM. Thyroid antigens, not central tolerance, control responses to immunization in BALB/c versus C57BL/6 mice. Thyroid. 2009;19: 503-509.
26. Muixí L, Carrascal M, Alvarez I, et al. Thyroglobulin peptides associate in vivo to HLA-DR in autoimmune thyroid glands. J Immunol. 2008;181:795-807.
27. Unanue ER, Cerottini JC. The immunogenicity of antigen bound to the plasma membrane of macrophages. J Exp Med. 1970;131:711-725.
28. Bergers JJ, Den Otter W, De Groot JW, et al. Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells. Cancer Immunol Immunother. 1992;34:233-240.
29. Stahl P, Gordon S. Expression of a mannosyl-fucosyl receptor for endocytosis on cultured primary macrophages and their hybrids. J Cell Biol. 1982;93:49-56.
30. Engering AJ, Cella M, Fluitsma D, et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol. 1997;27:2417-2425.
31. Chazenbalk GD, Pichurin PN, Guo J, Rapoport B, McLachlan SM. Interactions between the mannose receptor and thyroid autoantigens. Clin Exp Immunol. 2005; 139:216-224.
32. Tomer Y, Greenberg DA, Concepcion E, Ban Y, Davies TF. Thyroglobulin is a thyroid specific gene for the familial autoimmune thyroid diseases. J Clin Endocrinol Metab. 2002;87:404-407.
33. Brand OJ, Barrett JC, Simmonds MJ, et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet. 2009;18:1704-1713.
34. Adams DD, Kennedy TH, Stewart JC, Utiger RD, Vidor GI. Hyperthyroidism in Tasmania following iodide supplementation: measurements of thyroid-stimulating autoantibodies and thyrotropin. J Clin Endocrinol Metab. 1975;41:221-228.
35. Orgiazzi J, Williams DE, Chopra IJ, Solomon DH. Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease. J Clin Endocrinol Metab. 1976;42:341-354.
36. Endo K, Kasagi K, Konishi J, et al. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab. 1978;46:734-739.
37. Morshed SA, Ando T, Latif R, Davies TF. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. Endocrinology. 2010;151:5537-5549.
38. Khoo TK, Bahn RS. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid. 2007;17:1013-1018.
39. Rapoport B, McLachlan SM. Thyroid autoimmunity. J Clin Invest. 2001;108:1253-1259.
40. Campbell PN, Doniach D, Hudson RV, Roitt IM. Autoantibodies in Hashimoto's disease (lymphadenoid goitre). Lancet. 1956;271:820-821.
41. Belyavin G, TrotterWR.Investigations of thyroid antigens reacting with Hashimoto sera; evidence for an antigen other than thyroglobulin. Lancet. 1959;1:648-652.
42. Czarnocka B, Ruf J, Ferrand M, Carayon P, Lissitzky S. Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases. FEBS Lett. 1985;190:147-152.
43. Portmann L, Hamada N, Heinrich G, DeGroot LJ. Antithyroid peroxidase antibody in patients with autoimmune thyroid disease: possible identity with anti-microsomal antibody. J Clin Endocrinol Metab. 1985;61:1001-1003.
44. Seto P, Hirayu H, Magnusson RP, et al. Isolation of a complementary DNA clone for thyroid microsomal antigen. Homology with the gene for thyroid peroxidase. J Clin Invest. 1987;80:1205-1208.
45. Libert F, Ruel J, Ludgate M, et al. Thyroperoxidase, an auto-antigen with a mosaic structure made of nuclear and mitochondrial gene modules. EMBO J. 1987;6:4193-4196.
46. Blomgren H, Lundell G. Proliferation of peripheral lymphoid cells from euthyroid and hyperthyroid individuals cultured with human thyroglobulin. Acta Endocrinol (Copenh). 1979;90:227-232.
47. MacKenzie WA, Schwartz AE, Friedman EW, Davies TF. Intrathyroidal T cell clones from patients with autoim mune thyroid disease. J Clin Endocrinol Metab. 1987;64: 818-824.
48. Fukuma N, McLachlan SM, Rapoport B, et al. Thyroid autoantigens and human T cell responses. Clin Exp Immunol. 1990;82:275-283.
49. Fisfalen ME, Soliman M, Okamoto Y, Soltani K, DeGroot LJ. Proliferative responses of T-cells to thyroid antigens and synthetic thyroid peroxidase peptides in autoimmune thyroid disease. J Clin Endocrinol Metab. 1995;80:1597-1604.
50. Fisfalen ME, Palmer EM, Van Seventer GA, et al. Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab. 1997;82:3655-3663.
51. Rasooly L, Rose NR, Saboori AM, Ladenson PW, Burek CL. Iodine is essential for human T cell recognition of human thyroglobulin. Autoimmunity. 1998;27:213-219.
52. Prentice LM, Phillips DI, Sarsero D, Beever K, McLachlan SM, Smith BR. Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. Acta Endocrinol (Copenh). 1990; 123:493-498.
53. Yoshida H, Amino N, Yagawa K, et al. Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: Studies of seventy autopsied cases. J Clin Endocrinol Metab. 1978;46:859-862.
54. Acar T, Ozbek SS, Erdogan M, Ozgen AG, Demirel SO. US findings in euthyroid patients with positive antithyroid autoantibody tests compared to normal and hypothyroid cases. Diagn Interv Radiol. 2013;19:265-270.
55. Marcocci C, Chiovato L, Mariotti S, Pinchera A. Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves' disease. J Endocrinol Invest. 1982;5:13-19.
56. Allen EM, Appel MC, Braverman LE. The effect of iodide ingestion on the development of spontaneous lymphocytic thyroiditis in the diabetes-prone BB/W rat. Endocrinology. 1986;118:1977-1981.
57. Bernard NF, Ertug F, Margolese H. High incidence of thyroiditis and anti-thyroid autoantibodies inNODmice. Diabetes. 1992;41:40-46.
58. Rasooly L, Burek CL, Rose NR. Iodine-induced autoimmune thyroiditis in NOD-H-2h4 mice. Clin Immunol Immunopathol. 1996;81:287-292.
59. Braley-Mullen H, Sharp GC, Medling B, Tang H. Spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J Autoimmun. 1999;12:157-165.
60. Hutchings PR, Verma S, Phillips JM, Harach SZ, Howlett S, Cooke A. Both CD4(+) T cells and CD8(+) T cells are required for iodine accelerated thyroiditis in NOD mice. Cell Immunol. 1999;192:113-121.
61. Wick G, Most J, Schauenstein K, et al. Spontaneous autoimmune thyroiditis-a bird's eye view. Immunol Today. 1985;6:359-365.
62. Aichinger G, Kofler H, Diaz-Merida O, Wick G. Nonthyroid autoantibodies in obese strain (OS) chickens. Clin Immunol Immunopathol. 1984;32:57-69.
63. Tucker WE Jr. Thyroiditis in a group of laboratory dogs. A study of 167 beagles.AmJ Clin Pathol. 1962;38:70-74.
64. Thacker EL, Davis JM, Refsal KR, Bull RW. Isolation of thyroid peroxidase and lack of autoantibodies to the enzyme in dogs with autoimmune thyroid disease. Am J Vet Res. 1995;56:34-38.
65. LevyBM,Hampton S, Dreizen S, Hampton JK. Thyroiditis in the marmoset (Callithrix spp. and Saguinus spp.). J Comp Pathol. 1972;82:99-103.
66. David JM, Dick EJ Jr, Hubbard GB. Spontaneous pathology of the common marmoset (Callithrix jacchus) and tamarins (Saguinus oedipus, Saguinus mystax). J Med Primatol. 2009;38:347-359.
67. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med. 1995;181:1957-1963.
68. Serreze DV, Fleming SA, Chapman HD,Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 1998;161: 3912-3918.
69. Yu S, Maiti PK, Dyson M, Jain R, Braley-Mullen H. B Cell-deficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis. J Exp Med. 2006;203:349-358.
70. Vaughan AT, Roghanian A, Cragg MS. B cells-masters of the immunoverse. Int J Biochem Cell Biol. 2011;43:280-285.
71. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33-40.
72. Ueki I, Abiru N, KobayashiM,et al.Bcell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism. Clin Exp Immunol. 2011;163: 309-317.
73. Yassai M,AmmonK, Goverman J, Marrack P, Naumov Y, Gorski J. A molecular marker for thymocyte-positive selection: selection of CD4 single-positive thymocytes with shorter TCRB CDR3 during T cell development. J Immunol. 2002;168:3801-3807.
74. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell. 1987;49:273-280.
75. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol. 2001;2:1032-1039.
76. Ferguson BJ, Cooke A, Peterson P, Rich T. Death in the AIRE. Trends Immunol. 2008;29:306-312.
77. Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15:289-292.
78. Pugliese A, Zeller M, FernandezAJr, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 1997; 15:293-297.
79. Akkaraju S, Ho WY, Leong D, Canaan K, Davis MM, Goodnow CC. A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis. Immunity. 1997;7:255-271.
80. Zhang M, Vacchio MS, Vistica BP, et al. T cell tolerance to a neo-self antigen expressed by thymic epithelial cells: the soluble form is more effective than the membrane-bound form. J Immunol. 2003;170:3954-3962.
81. Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997;17:399-403.
82. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393-398.
83. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298:1395-1401.
84. Ramsey C, Winqvist O, Puhakka L, et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet. 2002; 11:397-409.
85. Mathis D, Benoist C.Adecade of AIRE. Nat Rev Immunol. 2007;7:645-650.
86. Kont V, Laan M, Kisand K, Merits A, Scott HS, Peterson P. Modulation of Aire regulates the expression of tissuerestricted antigens. Mol Immunol. 2008;45:25-33.
87. Liston A, Gray DH, Lesage S, et al. Gene dosage-limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med. 2004;200: 1015-1026.
88. Niki S, Oshikawa K, Mouri Y, et al. Alteration of intrapancreatic target-organ specificity by abrogation of Aire in NOD mice. J Clin Invest. 2006;116:1292-1301.
89. Jiang W, Anderson MS, Bronson R, Mathis D, Benoist C. Modifier loci condition autoimmunity provoked by Aire deficiency. J Exp Med. 2005;202:805-815.
90. Mouchess ML, Anderson M. Central tolerance induction [published online ahead of print May 10, 2013]. Curr Top Microbiol Immunol. doi:10.1007/82_2013_321.
91. Lourenço EV, La Cava A. Natural regulatory T cells in autoimmunity. Autoimmunity. 2011;44:33-42.
92. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activatedTcells expressing IL-2 receptorα-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
93. Rifa'I M, Kawamoto Y, Nakashima I, Suzuki H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med. 2004;200:1123-1134.
94. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108-116.
95. Wu AJ, Hua H, Munson SH, McDevitt HO. Tumor necrosis factor-α regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci U S A. 2002;99:12287-12292.
96. Endharti AT, Rifa'I M, Shi Z, et al. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-+ production and proliferation of CD8+T cells. J Immunol. 2005;175:7093-7097.
97. Thomas JW. Antigen-specific responses in autoimmunity and tolerance. Immunol Res. 2001;23:235-244.
98. Goodnow CC, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of selfreactive B lymphocytes in transgenic mice. Nature. 1988; 334:676-682.
99. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membranebound antigens. Nature. 1991;353:765-769.
100. Akkaraju S, Canaan K, Goodnow CC. Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells. J Exp Med. 1997;186:2005-2012.
101. Silveira PA, Dombrowsky J, Johnson E, Chapman HD, Nemazee D, Serreze DV. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol. 2004;172:5086-5094.
102. Luning Prak ET, Monestier M, Eisenberg RA. B cell receptor editing in tolerance and autoimmunity. Ann N Y Acad Sci. 2011;1217:96-121.
103. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221-241.
104. Lehmann B, Schwab I, BöhmS, Lux A, Biburger M, Nimmerjahn F. Fc+RIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol. 2012;8: 243-254.
105. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity. 2012;37:199-207.
106. Scholz JL, Cancro MP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunol Lett. 2012;143: 2-8.
107. Guéry L, Hugues S. Tolerogenic and activatory plasmacytoid dendritic cells in autoimmunity. Front Immunol. 2013;4:59.
108. Terplan KL, Witebsky E, Rose NR, Paine JR, Egan RW. Experimental thyroiditis in rabbits, guinea pigs and dogs, following immunization with thyroid extracts of their own and of heterologous species. Am J Pathol. 1960;36:213-239.
109. Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and autoimmunization. J AmMed Assoc. 1957;164:1439-1447.
110. Rose NR, Kite JH Jr, Doebbler TK, Spier R, Skelton FR, Witebsky E. Studies on experimental thyroiditis. Ann NY Acad Sci. 1965;124:201-230.
111. Pudifin DJ, Duursma J, Brain P. Experimental autoimmune thyroiditis in the vervet monkey. Clin Exp Immunol. 1977;29:256-260.
112. Kong YM. Experimental models for autoimmune thyroid disease: recent developments. In: Volpé R, ed. Autoimmune Endocrinopathies (Contemporary Endocrinology). Totawa, NJ: Humana Press; 2004:91-111.
113. Esquivel PS, Rose NR, Kong YC. Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide. J Exp Med. 1977;145: 1250-1263.
114. Kong YC, Lomo LC, Motte RW, et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med. 1996;184: 1167-1172.
115. Kotani T, Umeki K, Hirai K, Ohtaki S. Experimental murine thyroiditis induced by porcine thyroid peroxidase and its transfer by the antigen-specific T cell line. Clin Exp Immunol. 1990;80:11-18.
116. McLachlan SM, Atherton MC, Nakajima Y, et al. Thyroid peroxidase and the induction of autoimmune thyroid disease. Clin Exp Immunol. 1990;79:182-188.
117. Ng HP, Banga JP, Kung AW. Development of a murine model of autoimmune thyroiditis induced with homologous mouse thyroid peroxidase. Endocrinology. 2004; 145:809-816.
118. Kotani T, Umeki K, Yagihashi S, Hirai K, Ohtaki S. Identification of thyroiditogenic epitope on porcine thyroid peroxidase for C57BL/6 mice. J Immunol. 1992;148: 2084-2089.
119. Ng HP, Kung AW. Induction of autoimmune thyroiditis and hypothyroidism by immunization of immunoactive T cell epitope of thyroid peroxidase. Endocrinology. 2006; 147:3085-3092.
120. Costagliola S, Many MC, Stalmans-Falys M, Tonacchera M, Vassart G, Ludgate M. Recombinant thyrotropin receptor and the induction of autoimmune thyroid disease in BALB/c mice: a new animal model. Endocrinology. 1994; 135:2150-2159.
121. Costagliola S, Many MC, Stalmans-Falys M, Vassart G, Ludgate M. The autoimmune response induced by immunising female mice with recombinant human thyrotropin receptor varies with the genetic background. Molec Cell Endocrinol. 1995;115:199-206.
122. Silverman DA, Rose NR. Autoimmunity in methylcholanthrene-induced and spontaneous thyroiditis in Buffalo strain rats. Proc Soc Exp Biol Med. 1971;138:579-584.
123. Penhale WJ, Farmer A, McKenna RP, Irvine WJ. Spontaneous thyroiditis in thymectomized and irradiated Wistar rats. Clin Exp Immunol. 1973;15:225-236.
124. Silverman DA, Rose NR. Neonatal thymectomy increases the incidence of spontaneous and methylcholanthrene-enhanced thyroiditis in rats. Science. 1974;184:162-163.
125. Sharp GC, Mullen H, Kyriakos M. Production of augmented experimental autoimmune thyroiditis lesions by combined transfer of antiserum and lymph node cells. J Immunol. 1974;112:478-487.
126. Braley-Mullen H, Johnson M, Sharp GC, Kyriakos M. Induction of experimental autoimmune thyroiditis in mice with in vitro activated splenic T cells. Cell Immunol. 1985; 93:132-143.
127. Braley-Mullen H, Sharp GC. Adoptive transfer murine model of granulomatous experimental autoimmune thyroiditis. Int Rev Immunol. 2000;19:535-555.
128. Charreire J, Michel-Bechet M. Syngeneic sensitization of mouse lymphocytes on monolayers of thyroid epithelial cells. III. Induction of thyroiditis by thyroid-sensitized T lymphoblasts. Eur J Immunol. 1982;12:421-425.
129. Knight SC, Farrant J, Chan J, Bryant A, Bedford PA, Bateman C. Induction of autoimmunity with dendritic cells: studies on thyroiditis in mice. Clin Immunol Immunopathol. 1988;48:277-289.
130. Jaume JC, Guo J, Wang Y, Rapoport B, McLachlan SM. Cellular thyroid peroxidase (TPO), unlike purified TPO and adjuvant, induces antibodies in mice that resemble autoantibodies in human autoimmune thyroid disease. J Clin Endocrinol Metab. 1999;84:1651-1657.
131. Okayasu I, Hatakeyama S. The difference of susceptibility of target thyroid gland to autoimmune thyroiditis induced by a combination of implantation of thyroid gland and injection of lipopolysaccharide. Clin Immunol Immunopathol. 1983;29:51-57.
132. Flynn JC, Gardas A, Wan Q, et al. Superiority of thyroid peroxidase DNA over protein immunization in replicating human thyroid autoimmunity in HLA-DRB1*0301 (DR3) transgenic mice. Clin Exp Immunol. 2004;137:503-512.
133. Jacobson EM, Concepcion E, Ho K, Kopp P, Vono Toniolo J, Tomer Y. cDNA immunization of mice with human thyroglobulin generates both humoral and T cell responses: a novel model of thyroid autoimmunity. PLoS One. 2011;6:e19200.
134. Guo J, McLachlan SM, Pichurin PN, et al. Relationship between thyroid peroxidase T cell epitope restriction and antibody recognition of the autoantibody immunodominant region in human leukocyte antigen DR3 transgenic mice. Endocrinology. 2005;146:4961-4967.
135. Chen CR, Hamidi S, Braley-Mullen H, et al. Antibodies to thyroid peroxidase arise spontaneously with age in NOD.H-2h4mice and appear after thyroglobulin antibodies. Endocrinology. 2010;151:4583-4593.
136. Martin AP, Coronel EC, Sano G, et al. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J Immunol. 2004;173:4791-4798.
137. Akeno N, Smith EP, Stefan M, et al. IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol. 2011;186:4693-4706.
138. Martin AP, Marinkovic T, Canasto-Chibuque C, et al. CCR7 deficiency in NOD mice leads to thyroiditis and primary hypothyroidism. J Immunol. 2009;183:3073-3080.
139. Barin JG, Afanasyeva M, Talor MV, Rose NR, Burek CL, Caturegli P. Thyroid-specific expression of IFN-+ limits experimental autoimmune thyroiditis by suppressing lymphocyte activation in cervical lymph nodes. J Immunol. 2003;170:5523-5529.
140. Nagayama Y. Observations on the proposed "nonclassical" model of autoimmune hypothyroidism. Thyroid. 2010;20:665-666; author reply 666-667.
141. Todd I, Pujol-Borrell R, Hammond LJ, Bottazzo GF, FeldmannM. Interferon-α inducesHLA-DRexpression by thyroid epithelium. Clin Exp Immunol. 1985;61:265-273.
142. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 1983;2:1115-1119.
143. Quaratino S, Badami E, Pang YY, et al. Degenerate selfreactive human T-cell receptor causes spontaneous autoimmune disease in mice. Nat Med. 2004;10:920-926.
144. Badami E, Maiuri L, Quaratino S. High incidence of spontaneous autoimmune thyroiditis in immunocompetent self-reactive human T cell receptor transgenic mice. J Autoimmun. 2005;24:85-91.
145. Wei WZ, Jacob JB, Zielinski JF, et al. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res. 2005;65:8471-8478.
146. Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol. 2009;182: 5873-5881.
147. McLachlan SM, Nagayama Y, Pichurin PN, et al. The link between Graves' disease and Hashimoto's thyroiditis: A role for regulatory T cells. Endocrinology. 2007;148: 5724-5733.
148. Kong YC. Experimental autoimmune thyroiditis in the mouse. Curr Protoc Immunol. 2007;15:15.7.
149. Quaratino S, Thorpe CJ, Travers PJ, Londei M. Similar antigenic surfaces, rather than sequence homology, dictate T-cell epitope molecular mimicry. Proc Natl Acad SciUSA. 1995;92:10398-10402.
150. Nagayama Y. Graves' animal models of Graves' hyperthyroidism. Thyroid. 2007;17:981-988.
151. Kim-Saijo M, Akamizu T, Ikuta K, et al. Generation of a transgenic animal model of hyperthyroid Graves' disease. Eur J Immunol. 2003;33:2531-2538.
152. Akamizu T, Matsuda F, Okuda J, et al. Molecular analysis of stimulatory anti-thyrotropin receptor antibodies (TSAbs) involved in Graves' disease. Isolation and reconstruction of antibody genes, and production of monoclonal TSAbs. J Immunol. 1996;157:3148-3152.
153. Sanders J, Jeffreys J, Depraetere H, et al. Thyroid-stimulating monoclonal antibodies. Thyroid. 2002;12:1043-1050.
154. Costagliola S, Franssen JD, BonomiM,et al. Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. Biochem Biophys Res Commun. 2002;299: 891-896.
155. Ando T, Latif R, Pritsker A, Moran T, Nagayama Y, Davies TF. A monoclonal thyroid-stimulating antibody. J Clin Invest. 2002;110:1667-1674.
156. Sanders J, Evans M, Premawardhana LD, et al. Human monoclonal thyroid stimulating autoantibody. Lancet. 2003;362:126-128.
157. Shimojo N, Kohno Y, Yamaguchi K, et al. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci USA. 1996;93:11074-11079.
158. Yamaguchi K, Shimojo N, Kikuoka S, et al. Genetic control of anti-thyrotropin receptor antibody generation in H-2k mice immunized with thyrotropin receptor-transfected fibroblasts. J Clin Endocrinol Metab. 1997;82:4266-4269.
159. Kaithamana S, Fan J, Osuga Y, Liang SG, Prabhakar BS. Induction of experimental autoimmune Graves' disease in BALB/c mice. J Immunol. 1999;163:5157-5164.
160. Kita-Furuyama M, Nagayama Y, Pichurin P, McLachlan SM, Rapoport B, Eguchi K. Dendritic cells infected with adenovirus expressing the thyrotrophin receptor induce Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol. 2003;131:234-240.
161. Ando T, Imaizumi M, Graves P, Unger P, Davies TF. Induction of thyroid-stimulating hormone receptor autoimmunity in hamsters. Endocrinology. 2003;144:671-680.
162. Costagliola S, Rodien P,ManyMC,LudgateM,Vassart G. Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J Immunol. 1998;160:1458-1465.
163. Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vassart G. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J Clin Invest. 2000;105:803-811.
164. Nagayama Y, Kita-Furuyama M, Ando T, et al. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol. 2002;168:2789-2794.
165. ChenCR,Pichurin P,NagayamaY, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest. 2003;111:1897-1904.
166. Kaneda T, Honda A, Hakozaki A, Fuse T, Muto A, Yoshida T.Animproved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology. 2007;148:2335-2344.
167. Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011;210:369-377.
168. Gilbert JA, Gianoukakis AG, Salehi S, et al. Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways. J Immunol. 2006;176:5084-5092.
169. Huber AK, Finkelman FD, Li CW, et al. Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease. J Immunol. 2012;189:3043-3053.
170. Jacobson EM, Concepcion E, Oashi T, Tomer Y. A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology. 2005;146:2684-2691.
171. Rapoport B, Williams RW, Chen CR, McLachlan SM. Immunoglobulin heavy chain variable region genes contribute to the induction of thyroid-stimulating antibodies in recombinant inbred mice. Genes Immun. 2010;11:254-263.
172. Nakahara M, Mitsutake N, Sakamoto H, et al. Enhanced response to mouse thyroid-stimulating hormone (TSH) receptor immunization in TSH receptor-knockout mice. Endocrinology. 2010;151:4047-4054.
173. Marians RC, Ng L, Blair HC, Unger P, Graves PN, Davies TF. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc Natl Acad Sci USA. 2002;99: 15776-15881.
174. Nakahara M, Johnson K, Eckstein A, et al. Adoptive transfer of antithyrotropin receptor (TSHR) autoimmunity from TSHR knockout mice to athymic nude mice. Endocrinology. 2012;153:2034-2042.
175. McLachlan SM, Aliesky HA, Chen CR, Rapoport B. Role of self-tolerance and chronic stimulation in the long-term persistence of adenovirus-induced thyrotropin receptor antibodies in wild-type and transgenic mice. Thyroid. 2012;22:931-937.
176. Endo T, Kobayashi T. Immunization of mice with a newly identified thyroid-stimulating hormone receptor splice variant induces Graves'-like disease. J Autoimmun. 2013; 43:18-25.
177. Ng B, Yang F, Huston DP, et al. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol. 2004;114:1463-1470.
178. Melchers F, Rolink AR. B cell tolerance-how to make it and how to break it. Curr Top Microbiol Immunol. 2006; 305:1-23.
179. Roitt IM, Torrigiani G, Doniach D. Immunochemical studies on the thyroglobulin autoantibody system in human thyroiditis. Immunology. 1968;15:681-696.
180. Ruf J, Toubert ME, Czarnocka B, Durand-Gorde JM, Ferrand M, Carayon P. Relationship between immunological structure and biochemical properties of human thyroid peroxidase. Endocrinology. 1989;125:1211-1218.
181. Chazenbalk GD, Portolano S, Russo D, Hutchison JS, Rapoport B, McLachlan S. Human organ-specific autoimmune disease. Molecular cloning and expression of an autoantibody gene repertoire for a major autoantigen reveals an antigenic immunodominant region and restricted immunoglobulin gene usage in the target organ. J Clin Invest. 1993;92:62-74.
182. Latrofa F, Phillips M, Rapoport B, McLachlan SM. Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes. J Clin Endocrinol Metab. 2004;89:5116-5123.
183. Shimojo N, Arima T, Yamaguchi K, Kikuoka S, Kohn LD, Kohno Y. A novel mouse model of Graves' disease: implications for a role of aberrantMHCclass II expression in its pathogenesis. Int Rev Immunol. 2000;19:619-631.
184. Jaume JC, Guo J, Wang Y, Rapoport B, McLachlan SM. Cellular thyroid peroxidase (TPO), unlike purified TPO and adjuvant, induces antibodies in mice that resemble autoantibodies in human autoimmune thyroid disease. J Clin Endocrinol Metab. 1999;84:1651-1657.
185. McLachlan SM, Aliesky HA, Chen CR, Chong G, Rapoport B. Breaking tolerance in transgenic mice expressing the human TSH receptor A-subunit: thyroiditis, epitope spreading and adjuvant as a 'double edged sword'. PLoS One. 2012;7:e43517.
186. Brand OJ, Gough SC. Immunogenetic mechanisms leading to thyroid autoimmunity: recent advances in identifying susceptibility genes and regions. Curr Genomics. 2011;12: 526-541.
187. Ploski R, Szymański K, Bednarczuk T. The genetic basis of graves' disease. Curr Genomics. 2011;12:542-563.
188. Hasham A, Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res. 2012;54:204-213.
189. Dechairo BM, Zabaneh D, Collins J, et al. Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet. 2005;13:1223-1230.
190. Hiratani H, Bowden DW, Ikegami S, et al. Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease. J Clin Endocrinol Metab. 2005;90:2898-2903.
191. Colobran R, Armengol Mdel P, Faner R, et al. Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance.Hum Mol Genet. 2011;20:3415-3423.
192. Nithiyananthan R, Heward JM, Allahabadia A, Barnett AH, Franklyn JA, Gough SC. A heterozygous deletion of the autoimmune regulator (AIRE1) gene, autoimmune thyroid disease, and type 1 diabetes: no evidence for association. J Clin Endocrinol Metab. 2000;85:1320-1322.
193. Meyer G, Donner H, Herwig J, Böhles H, Usadel KH, Badenhoop K. Screening for an AIRE-1 mutation in patients with Addison's disease, type 1 diabetes, Graves' disease and Hashimoto's thyroiditis as well as in APECED syndrome. Clin Endocrinol (Oxf). 2001;54:335-338.
194. Perniola R, Filograna O, Greco G, Pellegrino V. High prevalence of thyroid autoimmunity in Apulian patients with autoimmune polyglandular syndrome type 1. Thyroid. 2008;18:1027-1029.
195. Björses P, Halonen M, Palvimo JJ, et al. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy protein. Am J Hum Genet. 2000;66:378-392.
196. Scott HS, Heino M, Peterson P, et al. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol. 1998;12:1112-1119.
197. Cetani F, Barbesino G, Borsari S, et al. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 2001;86:4747-4752.
198. Su MA, Giang K, Zumer K, et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest. 2008;118:1712-1726.
199. Stenszky V, Kozma L, Balázs C, Rochlitz S, Bear JC, Farid NR. The genetics of Graves' disease: HLA and disease susceptibility. J Clin Endocrinol Metab. 1985;61:735-740.
200. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329-1337.
201. Ban Y, Davies TF, Greenberg DA, et al. Arginine at position 74 of the HLA-DR+1 chain is associated with Graves' disease. Genes Immun. 2004;5:203-208.
202. Kong YC, Flynn JC, Banga JP, David CS. Application of HLA class II transgenic mice to study autoimmune regulation. Thyroid. 2007;17:995-1003.
203. Aliesky HA, Pichurin PN, Chen CR, Williams RW, Rapoport B, McLachlan SM. Probing the genetic basis for thyrotropin receptor antibodies and hyperthyroidism in immunized CXB recombinant inbred mice. Endocrinology. 2006;147:2789-2800.
204. McLachlan SM, Aliesky HA, Pichurin PN, Chen CR, Williams RW, Rapoport B. Shared and unique susceptibility genes in a mouse model of Graves' disease determined in BXH and CXB recombinant inbred mice. Endocrinology. 2008;149:2001-2009.
205. McLachlanSM,Aliesky H,ChenCR,WilliamsRW,Rapoport B. Exceptional hyperthyroidism and a role for both major histocompatibility class I and class II genes in a murine model of Graves' disease. PLoS One. 2011;6:e21378.
206. Chu X, Pan CM, Zhao SX, et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet. 2011;43:897-901.
207. Tomer Y, Greenberg DA, Concepcion E, Ban Y, Davies TF. Thyroglobulin is a thyroid specific gene for the familial autoimmune thyroid diseases. J Clin Endocrinol Metab. 2002;87:404-407.
208. Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci USA. 2003;100:15119-15124.
209. Jacobson EM, Yang H, Menconi F, et al. Employing a recombinantHLA-DR3expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective. J Biol Chem. 2009;284:34231-34243.
210. Brand OJ, Lowe CE, Heward JM, et al. Association of the interleukin-2 receptor α (IL-2Rα)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol Oxf. 2007;66:508-512.
211. Owen CJ, Eden JA, Jennings CE, Wilson V, Cheetham TD, Pearce SH. Genetic association studies of the FOXP3 gene in Graves' disease and autoimmune Addison's disease in the United Kingdom population. J Mol Endocrinol. 2006; 37:97-104.
212. Tomer Y, Menconi F, Davies TF, et al. Dissecting genetic heterogeneity in autoimmune thyroid diseases by subset analysis. J Autoimmun. 2007;29:69-77.
213. Kekäläinen E, Tuovinen H, Joensuu J, et al. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Immunol. 2007;178:1208-1215.
214. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, De-Groot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab. 1995;80:41-45.
215. Maine CJ, Hamilton-Williams EE, Cheung J, et al. PTPN22 alters the development of regulatory T cells in the thymus. J Immunol. 2012;188:5267-5275.
216. Vasícek D, Vasícková K, Kaiser P, Drozenová R, Cítek J, Hala K. Analysis of genetic regulation of chicken spontaneous autoimmune thyroiditis, an animal model of human Hashimoto's thyroiditis. Immunogenetics. 2001;53:776-785.
217. Weetman AP. Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol. 2010;6:311-318.
218. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. Immunol Res. 2012; 54:191-203.
219. Imaizumi M, Pritsker A, Unger P, Davies TF. Intrathyroidal fetal microchimerism in pregnancy and postpartum. Endocrinology. 2002;143:247-253.
220. Walsh JP, Bremner AP, Bulsara MK, et al. Parity and the risk of autoimmune thyroid disease: a community-based study. J Clin Endocrinol Metab. 2005;90:5309-5312.
221. Bülow Pedersen I, Laurberg P, Knudsen N, et al. Lack of association between thyroid autoantibodies and parity in a population study argues against microchimerism as a trigger of thyroid autoimmunity. Eur J Endocrinol. 2006;154: 39-45.
222. Sgarbi JA, Kasamatsu TS, Matsumura LK, Maciel RM. Parity is not related to autoimmune thyroid disease in a population-based study of Japanese-Brazilians. Thyroid. 2010;20:1151-1156.
223. Brix TH, Hansen PS, Kyvik KO, Hegedüs L. Aggregation of thyroid autoantibodies in twins from opposite-sex pairs suggests that microchimerism may play a role in the early stages of thyroid autoimmunity. J Clin Endocrinol Metab. 2009;94:4439-4443.
224. Greer LG, Casey BM, Halvorson LM, Spong CY, McIntire DD, Cunningham FG. Antithyroid antibodies and parity: further evidence for microchimerism in autoimmune thyroid disease. Am J Obstet Gynecol. 2011;205:471-474.
225. Misharin AV, Nagayama Y, Aliesky HA, Rapoport B, McLachlan SM. Studies in mice deficient for the autoimmune regulator (Aire) and transgenic for the thyrotropin receptor reveal a role for Aire in tolerance for thyroid autoantigens. Endocrinology. 2009;150:2948 -2956.
226. Pichurin PN, Chen CR, Chazenbalk GD, et al. Targeted expression of the human thyrotropin receptor A-subunit to the mouse thyroid: Insight into overcoming the lack of response to A-subunit adenovirus immunization. J Immunol. 2006;176:668-676.
227. PurcellAW,van Driel IR, Gleeson PA. Impact of glycans on T-cell tolerance to glycosylated self-antigens. Immunol Cell Biol. 2008;86:574-579.
228. Szabó TG, Palotai R, Antal P, et al. Critical role of glycosylation in determining the length and structure of T cell epitopes. Immunome Res. 2009;5:4.
229. Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B, Germeraad WT. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res. 2007;67:3919-3926.
230. Feldt-Rasmussen U, Hyltoft Petersen P, Date J. Sex and age correlated reference values of serum thyroglobulin measured by a modified radioimmunoassay. Acta Endocrinol (Copenh). 1979;90:440-450.
231. Premawardhana LD, Kiso Y, Phillips DI, Morteo C, Furmaniak J, Rees Smith B. Is TPO detectable in the circulation? Thyroid. 1993;3:225-228.
232. Jacobson EM, Tomer Y. The genetic basis of thyroid autoimmunity. Thyroid. 2007;17:949-961.
233. Ruan QG, Tung K, Eisenman D, et al. The autoimmune regulator directly controls the expression of genes critical for thymic epithelial function. J Immunol. 2007;178: 7173-7180.
234. Lima FA, Moreira-Filho CA, Ramos PL, et al. Decreased AIRE expression and global thymic hypofunction inDown syndrome. J Immunol. 2011;187:3422-3430.
235. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Annerén G. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child. 1998;79: 242-245.
236. Mizutori Y, Nagayama Y, Flower D, et al. Role of the transgenic human thyrotropin receptor A-subunit in thyroiditis induced by A-subunit immunization and regulatory T cell depletion. Clin Exp Immunol. 2008;154:305-315.
237. Saitoh O, Nagayama Y. Regulation of Graves' hyperthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology. 2006;147: 2417-2422.
238. Saitoh O, Abiru N, Nakahara M, Nagayama Y. CD8+CD122+ T cells, a newly identified regulatory T subset, negatively regulate Graves' hyperthyroidism in a murine model. Endocrinology. 2007;148:6040-6046.
239. Johnson KT, Wiesweg B, Schott M, et al. Examination of orbital tissues in murine models of Graves' disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues. Horm Metab Res. 2013;45:401-407.
240. Chen CR, Aliesky HA, Rapoport B, McLachlan SM. An attempt to induce "Graves' disease of the gonads" by immunizing mice with the luteinizing hormone receptor provides insight into breaking tolerance to self-antigens. Thyroid. 2011;21:773-781.
241. Kojima A, Tanaka-Kojima Y, Sakakura T, Nishizuka Y. Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice. Lab Invest. 1976;34: 550-557.
242. Kong YC, Morris GP, Brown NK, Yan Y, Flynn JC, David CS. Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function. J Autoimmun. 2009;33: 239-246.
243. Morris GP, Brown NK, Kong YC. Naturally-existing CD4(+)CD25(+)Foxp3(+) regulatoryTcells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen. J Autoimmun. 2009;33:68-76.
244. Nagayama Y, Horie I, Saitoh O, Nakahara M, Abiru N. CD4+CD25+ naturally occurring regulatory T cells and not lymphopenia play a role in the pathogenesis of iodideinduced autoimmune thyroiditis in NOD-H2h4 mice. J Autoimmun. 2007;29:195-202.
245. Flynn JC, Meroueh C, Snower DP, David CS, Kong YM. Depletion of CD4+CD25+regulatory T cells exacerbates sodium iodide-induced experimental autoimmune thyroiditis in human leucocyte antigen DR3 (DRB1*0301) transgenic class II-knock-out non-obese diabetic mice. Clin Exp Immunol. 2007;147:547-554.
246. Morris GP, Yan Y, David CS, Kong YC. H2A-and H2Ederived CD4+CD25+ regulatory T cells: a potential role in reciprocal inhibition by class II genes in autoimmune thyroiditis. J Immunol. 2005;174:3111-3116.
247. Horie I, Abiru N, Sakamoto H, Iwakura Y, Nagayama Y. Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-α receptor, knockout nonobese diabetic-H2h4 mice. Endocrinology. 2011;152:4448-4454.
248. Marazuela M, García-López MA, Figueroa-Vega N, et al. Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab. 2006;91:3639-3646.
249. Nakano A, Watanabe M, Iida T, et al. Apoptosis-induced decrease of intrathyroidal CD4(+)CD25(+) regulatory T cells in autoimmune thyroid diseases. Thyroid. 2007;17: 25-31.
250. Strieder TG, Drexhage HA, Lam-Tse WK, Prummel MF, Tijssen JG, Wiersinga WM. A reduced IL2R (CD25) expression level in first and second degree female relatives of autoimmune thyroid disease patients. A sign of a poor capability to preserve tolerance. Autoimmunity. 2006;39: 93-98.
251. Volpé R, Iitaka M. Evidence for an antigen-specific defect in suppressor T-lymphocytes in autoimmune thyroid disease. Exp Clin Endocrinol. 1991;97:133-138.
252. Kohno Y, Naito N, Hiyama Y, et al. Thyroglobulin and thyroid peroxidase share common epitopes recognized by autoantibodies in patients with chronic autoimmune thyroiditis. J Clin Endocrinol Metab. 1988;67:899-907.
253. Ruf J, Ferrand M, Durand-Gorde JM, Carayon P. Immunopurification and characterization of thyroid autoantibodies with dual specificity for thyroglobulin and thyroperoxidase. Autoimmunity. 1992;11:179-188.
254. Naito N, Saito K, Hosoya T, et al. Anti-thyroglobulin autoantibodies in sera from patients with chronic thyroiditis and from healthy subjects: differences in cross-reactivity with thyroid peroxidase. Clin Exp Immunol. 1990;80:4-10.
255. Ruf J, Ferrand M, Durand-Gorde JM, De Micco C, Carayon P. Significance of thyroglobulin antibodies crossreactive with thyroperoxidase (TGPO antibodies) in individual patients and immunized mice. Clin Exp Immunol. 1993;92:65-72.
256. Ruf J, Feldt-Rasmussen U, Hegedüs L, Ferrand M, Carayon P. Bispecific thyroglobulin and thyroperoxidase autoantibodies in patients with various thyroid and autoimmune diseases. J Clin Endocrinol Metab. 1994;79: 1404-1409.
257. Estienne V, Duthoit C, Costanzo VD, et al. Multicenter study on TGPO autoantibody prevalence in various thyroid and non-thyroid diseases; relationships with thyroglobulin and thyroperoxidase autoantibody parameters. Eur J Endocrinol. 1999;141:563-569.
258. Latrofa F, Pichurin P, Guo J, Rapoport B, McLachlan SM. Thyroglobulin-thyroperoxidase autoantibodies are polyreactive, not bispecific: analysis using human monoclonal autoantibodies. J Clin Endocrinol Metab. 2003;88:371-378.
259. McLachlanSM,Rapoport B. Evidence for a potential commonT-cell epitope betweenhumanthyroid peroxidase and human thyroglobulin with implications for the pathogenesis of autoimmune thyroid disease. Autoimmunity. 1989; 5:101-106.
260. Rothbard JB, Taylor WR. A sequence pattern common to T cell epitopes. EMBO J. 1988;7:93-100.
261. Hoshioka A, Kohno Y, Katsuki T, et al. A common T-cell epitope between human thyroglobulin and human thyroid peroxidase is related to murine experimental autoimmune thyroiditis. Immunol Lett. 1993;37:235-239.
262. Ehlers M, Thiel A, Bernecker C, et al. Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto's thyroiditis. J Clin Endocrinol Metab. 2012;97:1347-1354.
263. McLachlan SM, Rapoport B. Recombinant thyroid autoantigens: the keys to the pathogenesis of autoimmune thyroid disease. J Intern Med. 1993;234:347-359.
264. Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM. Natural history of the transition from euthyroidism to overt autoimmune hypo-or hyperthyroidism: a prospective study. Eur J Endocrinol. 2011;164:107-113.
265. de Forteza R, Smith CU, Amin J, McKenzie JM, Zakarija M. Visualization of the thyrotropin receptor on the cell surface by potent autoantibodies. J Clin Endocrinol Metab. 1994;78:1271-1273.
266. Jaume JC, Kakinuma A, Chazenbalk GD, Rapoport B, McLachlan SM. Thyrotropin receptor autoantibodies in serum are present at much lower levels than thyroid peroxidase autoantibodies: analysis by flow cytometry. J Clin Endocrinol Metab. 1997;82:500-507.
267. Chazenbalk GD, McLachlan SM, Pichurin P, Yan XM, Rapoport B. A prion-like shift between two conformational forms of a recombinant thyrotropin receptor A-subunit module: purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies. J Clin Endocrinol Metab. 2001;86:1287-1293.
268. Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease. Thyroid. 2003;13:547-551.
269. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun. 2010;34:J322-J326.
270. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992;102:2155-2160.
271. Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest. 1997;20:374-380.
272. Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by α-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf). 2002;56:793-798.
273. Nagayama Y, Ohta K, Tsuruta M, et al. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J. 1994;41:565-572.
274. Marazuela M, García-Buey L, Gonzá lez-Fernández B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin Endocrinol (Oxf). 1996;44:635-642.
275. Martocchia A, Labbadia G, Paoletti V, et al. Hashimoto's disease during interferon-α therapy in a patient with pretreatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro Endocrinol Lett. 2001;22:49-52.
276. Baudin E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant α interferon in chronic hepatitis C. Clin Endocrinol (Oxf). 1993;39: 657-661.
277. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab. 2001;86: 1925-1929.
278. Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf). 2008;68:117-121.
279. WeetmanA.Immunereconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:693-702.
280. Holland FJ, McConnon JK, Volpé R, Saunders EF. Concordant Graves' disease after bone marrow transplantation: implications for pathogenesis. J Clin Endocrinol Metab. 1991;72:837-840.
281. Karthaus M, Gabrysiak T, Brabant G, et al. Immune thyroiditis after transplantation of allogeneicCD34+selected peripheral blood cells. Bone Marrow Transplant. 1997; 20:697-699.
282. Au WY, Lie AK, Kung AW, Liang R, Hawkins BR, Kwong YL. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005; 35:383-388.
283. Sinha A, Abinun M, Gennery AR, Barge D, Slatter M, Cheetham T. Graves' immune reconstitution inflammatory syndrome in childhood. Thyroid. 2013;23:1010-1014.
284. Zomas A, Marsh JC, Harrison NK, et al. Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia. Ann Hematol. 1995;71:49-51.
285. ToddA,ToddJ. Graves' disease following successful treatment of severe aplastic anaemia with antilymphocyte globulin. Clin Lab Haematol. 1999;21:69-70.
286. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691-1695.
287. Gillard P, Huurman V, Van der Auwera B, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPOautoantibodies. Diabetes Care. 2009;32:1817-1819.
288. Gilquin J, Viard JP, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet. 1998;352:1907-1908.
289. Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85:4254-4257.
290. Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore). 2005;84:98-106.
291. Rasul S, Delapenha R, Farhat F, Gajjala J, Zahra SM. Graves' disease as a manifestation of immune reconstitution in HIV-infected individuals after initiation of highly active antiretroviral therapy. AIDS Res Treat. 2011;2011: 743597.
292. Visser R, de Mast Q, Netea-Maier RT, van der Ven AJ. Hashimoto's thyroiditis presenting as painful acute thyroiditis and as manifestation of an immune reconstitution inflammatory syndrome in a human immunodeficiency virus-seropositive patient. Thyroid. 2012;22:853-855.
293. Duarte JH, Zelenay S, Bergman ML, Martins AC, Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol. 2009;39:948-955.
294. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117:265-277.
295. GallegosAM,Bevan MJ. Driven to autoimmunity: the nod mouse. Cell. 2004;117:149-151.
296. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-1801.
297. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-β are required for differentiation of human T(H)17 cells. Nature. 2008;454:350-352.
298. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119:2052-2061.
299. Kuchen S, Robbins R, Sims GP, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation duringCD4+Tcell-B cell collaboration. JImmunol. 2007; 179:5886-5896.
300. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+T lymphocytes. J Immunol. 2007;178:732-739.
301. Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30:99-105.
302. Chen K, Wei Y, Sharp GC, Braley-Mullen H. Induction of experimental autoimmune thyroiditis in IL-12-/- mice. J Immunol. 2001;167:1720-1727.
303. Nagayama Y, Saitoh O, McLachlan SM, Rapoport B, Kano H, Kumazawa Y. TSH receptor-adenovirusinduced Graves' hyperthyroidism is attenuated in both interferon-α and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm. Clin Exp Immunol. 2004;138:417-422.
304. Furtado GC, Marinkovic T, Martin AP, et al. Lymphotoxin α receptor signaling is required for inflammatory lymphangiogenesis in the thyroid. Proc Natl Acad SciUSA. 2007;104:5026-5031.
305. Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J Immunol. 2005;174:7433-7439.
306. Braley-Mullen H, Sharp GC, Tang H, Chen K, Kyriakos M, Bickel JT. Interleukin-12 promotes activation of effector cells that induce a severe destructive granulomatous form of murine experimental autoimmune thyroiditis. Am J Pathol. 1998;152:1347-1358.
307. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibodymediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol. 2003;170:3522-3527.
308. Saitoh O, Mizutori Y, Takamura N, et al. Adenovirusmediated gene delivery of interleukin-10, but not transforming growth factor α, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol. 2005;141:405-411.
309. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B. Schistosoma mansoni and α-galactosylceramide: prophylactic effect of Th1 Immune suppression in a mouse model of Graves' hyperthyroidism. J Immunol. 2004;173:2167-2173.
310. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16:709-710.
311. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab. 2007;92:1769-1772.
312. Gilbert JA, Kalled SL, Moorhead J, et al. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology. 2006;147:4561-4568.
313. McMaster PR, Kyriakos M. The prevention of autoimmunity to the thyroid and allergic thyroiditis by antigenic competition. J Immunol. 1970;105:1201-1205.
314. Sharp GC, Wortis HH, LaRoque RL, Mullen H, Kyriakos M. Protection against autoimmune thyroiditis in guinea pigs by thyroglobulin antiserum. J Immunol. 1974;112: 468-477.
315. Silverman DA, Rose NR. Inhibition of genetically determined autoimmune disease by organ-specific antigen. Lancet. 1974;1:1257-1258.
316. Whitmore DB, Irvine WJ. Prevention of autoimmune thyroiditis inTcell-depleted rats by injections of crude thyroid extract. Clin Exp Immunol. 1977;29:474-479.
317. Lewis M, Giraldo AA, Kong YC. Resistance to experimental autoimmune thyroiditis induced by physiologic manipulation of thyroglobulin level. Clin Immunol Immunopathol. 1987;45:92-104.
318. Lewis M, Fuller BE, Giraldo AA, Kong YC. Resistance to experimental autoimmune thyroiditis is correlated with the duration of raised thyroglobulin levels. Clin Immunol Immunopathol. 1992;64:197-204.
319. Hutchings PR, Parish NM, Cooke A. Abnormalities in the SJL mouse provide evidence for different mechanisms for the induction and transfer of tolerance to mouse thyroglobulin. Immunology. 1989;66:106-110.
320. Kong YM, Okayasu I, Giraldo AA, et al. Tolerance to thyroglobulin by activating suppressor mechanisms. Ann NY Acad Sci. 1982;392:191-209.
321. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779.
322. Misharin AV, Nagayama Y, Aliesky HA, Mizutori Y, Rapoport B, McLachlan SM. Attenuation of induced hyperthyroidism in mice by pretreatment with thyrotropin receptor protein: deviation of thyroid-stimulating to nonfunctional antibodies. Endocrinology. 2009;150:3944-3952.
323. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev. 2011;241:241-259.
324. Peterson KE, Braley-Mullen H. Suppression of murine experimental autoimmune thyroiditis by oral administration of porcine thyroglobulin. Cell Immunol. 1995;166:123-130.
325. Guimaraes VC, Quintans J, Fisfalen ME, et al. Suppression of development of experimental autoimmune thyroiditis by oral administration of thyroglobulin. Endocrinology. 1995;136:3353-3359.
326. Guimaraes VC, Quintans J, Fisfalen ME, et al. Immuno-suppression of thyroiditis. Endocrinology. 1996;137: 2199-2207.
327. Rapoport B, McLachlan SM. Food for thought-is induction of oral tolerance feasible and practical in human thyroid autoimmunity? Endocrinology. 1996;137:2197-2198.
328. Weetman AP, Yateman ME, Ealey PA, et al. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest. 1990;86:723-727.
329. Latrofa F, Chazenbalk GD, Pichurin P, Chen CR, McLachlan SM, Rapoport B. Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies. J Clin Endocrinol Metab. 2004;89:4734-4745.
330. Lee S, Scherberg N, DeGroot LJ. Induction of oral tolerance in human autoimmune thyroid disease. Thyroid. 1998;8:229-234.
331. Saegusa K, Ishimaru N, Haneji N, et al. Mechanisms of neonatal tolerance induced in an animal model for primary Sjögren's syndrome by intravenous administration of autoantigen. Scand J Immunol. 2000;52:264-270.
332. Wu L, Xun L, Yang J, et al. Induction of murine neonatal tolerance against Graves' disease using recombinant adenovirus expressing the TSH receptor A-subunit. Endocrinology. 2011;152:1165-1171.
333. Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases. Eur J Endocrinol. 2004;150:605-618.
334. Brent GA. Environmental exposures and autoimmune thyroid disease. Thyroid. 2010;20:755-761.
335. Burek CL, Talor MV. Environmental triggers of autoimmune thyroiditis. J Autoimmun. 2009;33:183-189.
336. Mori K, Nakagawa Y, Ozaki H. Does the gut microbiota trigger Hashimoto's thyroiditis? Discov Med. 2012;14: 321-326.
337. Dang MN, Buzzetti R, Pozzilli P. Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes Metab Res Rev. 2013;29:8-18.
338. Ingbar SH. Autoregulation of the thyroid. Response to iodide excess and depletion. Mayo Clin Proc. 1972;47:814-823.
339. Braverman LE, Ingbar SH, Vagenakis AG, Adams L, Maloof F. Enhanced susceptibility to iodide myxedema in patients with Hashimoto's disease. J Clin Endocrinol Metab. 1971;32:515-521.
340. Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid. 1998;8:83-100.
341. Wolff J. Iodide goiter and the pharmacologic effects of excess iodide. Am J Med. 1969;47:101-124.
342. Pedersen IB, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Laurberg P. Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxf). 2003; 58:36-42.
343. Bagchi N, Brown TR, Urdanivia E, Sundick RS. Induction of autoimmune thyroiditis in chickens by dietary iodine. Science. 1985;230:325-327.
344. Li HS, Carayanniotis G. Induction of goitrous hypothyroidism by dietary iodide in SJL mice. Endocrinology. 2007;148:2747-2752.
345. Carayanniotis G. Molecular parameters linking thyroglobulin iodination with autoimmune thyroiditis. Hormones (Athens). 2011;10:27-35.
346. Li HS, Verginis P, Carayanniotis G. Maturation of dendritic cells by necrotic thyrocytes facilitates induction of experimental autoimmune thyroiditis. Clin Exp Immunol. 2006;144:467-474.
347. Kawashima A, Yamazaki K, Hara T, et al. Demonstration of innate immune responses in the thyroid gland: potential to sense danger and a possible trigger for autoimmune reactions. Thyroid. 2013;23:477-487.
348. McLachlan SM, Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies? Thyroid. 2004;14:510-520.
349. Li HS, Carayanniotis G. Iodination of tyrosyls in thyroglobulin generates neoantigenic determinants that cause thyroiditis. J Immunol. 2006;176:4479-4483.
350. Kolypetri P, Noel NA, Carayanniotis KA, Carayanniotis G. Iodine content of thyroglobulin in Nod.H2h4 mice developing iodine-accelerated autoimmune thyroiditis. Hormones (Athens). 2010;9:151-160.
351. Duntas LH. The role of selenium in thyroid autoimmunity and cancer. Thyroid. 2006;16:455-460.
352. Bülow Pedersen I, Knudsen N, Carlé A, et al. Serum selenium is low in newly diagnosed Graves' disease: a population-based study. Clin Endocrinol Oxf. 2013;79(4): 584-590.
353. Duntas LH. Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab. 2010;95:5180-5188.
354. Chesney AM, Clawson TA, Webster B. Endemic goiter in rabbits. Bull Johns Hopkins Hosp. 1928;43:261.
355. Chu M, Seltzer TF. Myxedema coma induced by ingestion of raw bok choy. N Engl J Med. 2010;362:1945-1946.
356. Eheman CR, Garbe P, Tuttle RM. Autoimmune thyroid disease associated with environmental thyroidal irradiation. Thyroid. 2003;13:453-464.
357. Pacini F, Vorontsova T, Molinaro E, et al. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet. 1998;352:763-766.
358. Imaizumi M, Usa T, Tominaga T, et al. Radiation doseresponse relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA. 2006;295:1011-1022.
359. Agate L, Mariotti S, Elisei R, et al. Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiationinduced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. J Clin Endocrinol Metab. 2008;93:2729-2736.
360. McGregor AM, Petersen MM, Capiferri R, Evered DC, Smith BR, Hall R. Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves' disease. Clin Endocrinol (Oxf). 1979;11:437-444.
361. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227-3232.
362. DunkelmannS, Wolf R,KochA, Kittner C, Groth P, Schuemichen C. Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J NuclMedMolImaging. 2004; 31:1428-1434.
363. McGregor AM, McLachlan SM, Smith BR, Hall R. Effect of irradiation on thyroid-autoantibody production. Lancet. 1979;2:442-444.
364. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69-75.
365. Nagayama Y, Kaminoda K, Mizutori Y, Saitoh O, Abiru N. Exacerbation of autoimmune thyroiditis by a single low dose of whole-body irradiation in non-obese diabetic-H2h4 mice. Int J Radiat Biol. 2008;84:761-769.
366. Nagayama Y, Ichikawa T, Saitoh O, Abiru N. Induction of late-onset spontaneous autoimmune thyroiditis by a single low-dose irradiation in thyroiditis-prone non-obese diabetic-H2h4 mice. J Radiat Res. 2009;50:573-577.
367. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79:145-151.
368. Effraimidis G, Tijssen JG, Wiersinga WM. Discontinuation of smoking increases the risk for developing thyroid peroxidase antibodies and/or thyroglobulin antibodies: a prospective study. J Clin Endocrinol Metab. 2009;94: 1324-1328.
369. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol. 2009; 183:6681-6688.
370. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:723-733.
371. Silverman DA, Rose NR. Spontaneous and methylcholanthrene-enhanced thyroiditis in BUF rats. I. The incidence and severity of the disease, and the genetics of susceptibility. J Immunol. 1975;114:145-147.
372. Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. Endocr Rev. 1993;14:107-120.
373. Pozzilli P, Signore A, Williams AJ, Beales PE.NODmouse colonies around the world-recent facts and figures. Immunol Today. 1993;14:193-196.
374. Pichurin P, Yan XM, Farilla L, et al. Naked TSH receptor DNA vaccination: a TH1 T cell response in which interferon-α production, rather than antibody, dominates the immune response in mice. Endocrinology. 2001;142: 3530-3536.
375. Nagayama Y, McLachlan SM, Rapoport B, Niwa M. A major role for non-major histocompatibility complex genes but not for microorganisms in a novel murine model of Graves' hyperthyroidism. Thyroid. 2003;13: 233-238.
376. Weiss M, Ingbar SH, Winblad S, Kasper DL. Demonstration of a saturable binding site for thyrotropin in Yersinia enterocolitica. Science. 1983;219:1331-1333.
377. Bech K, Larsen JH, Hansen JM, Nerup J. Letter: Yersinia enterocolitica infection and thyroid disorders. Lancet. 1974;2:951-952.
378. Wenzel BE, Heesemann J, Wenzel KW, Scriba PC. Antibodies to plasmid-encoded proteins of enteropathogenic Yersinia in patients with autoimmune thyroid disease. Lancet. 1988;1:56.
379. Yamamoto M, Rapoport B. Studies on the binding of radiolabeled thyrotropin to cultured human thyroid cells. Endocrinology. 1978;103:2011-2019.
380. Luo G, Fan JL, Seetharamaiah GS, et al. Immunization of mice with Yersinia enterocolitica leads to the induction of antithyrotropin receptor antibodies. J Immunol. 1993; 151:922-928.
381. Luo G, Seetharamaiah GS, Niesel DW, et al. Purification and characterization of Yersinia enterocolitica envelope proteins which induce antibodies that react with human thyrotropin receptor. J Immunol. 1994;152:2555-2561.
382. Zhang H, Kaur I, Niesel DW, et al. Lipoprotein from Yersinia enterocolitica contains epitopes that cross-react with the human thyrotropin receptor. J Immunol. 1997;158: 1976-1983.
383. Zhang H, Kaur I, Niesel DW, et al. Yersinia enterocolitica envelope proteins that are crossreactive with the thyrotropin receptor (TSHR) also have B-cell mitogenic activity. J Autoimmun. 1996;9:509-516.
384. Gangi E, Kapatral V, El-Azami El-Idrissi M, Martinez O, Prabhakar BS. Characterization of a recombinant Yersinia enterocolitica lipoprotein; implications for its role in autoimmune response against thyrotropin receptor. Autoimmunity. 2004;37:515-520.
385. Wang Z, Zhang Q, Lu J, et al. Identification of outer membrane porin f protein of Yersinia enterocolitica recognized by antithyrotopin receptor antibodies in Graves' disease and determination of its epitope using mass spectrometry and bioinformatics tools. J Clin Endocrinol Metab. 2010; 95:4012-4020.
386. Guarneri F, Carlotta D, Saraceno G, Trimarchi F, Benvenga S. Bioinformatics support the possible triggering of autoimmune thyroid diseases by Yersinia enterocolitica outer membrane proteins homologous to the human thyrotropin receptor. Thyroid. 2011;21:1283-1284.
387. Corapçioglu D, Tonyukuk V, Kiyan M, et al. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies. Thyroid. 2002;12:613-617.
388. Effraimidis G, Tijssen JG, Strieder TG, Wiersinga WM. No causal relationship between Yersinia enterocolitica infection and autoimmune thyroid disease: evidence from a prospective study. Clin Exp Immunol. 2011;165: 38-43.
389. Brix TH, Hansen PS, Hegedüs L, Wenzel BE. Too early to dismiss Yersinia enterocolitica infection in the aetiology of Graves' disease: evidence from a twin case-control study. Clin Endocrinol (Oxf). 2008;69:491-496.
390. Hargreaves CE, Grasso M, Hampe CS, et al. Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves' disease. J Immunol. 2013;190:5373-5381.
391. Kraemer MH, Donadi EA, Tambascia MA, Magna LA, Prigenzi LS. Relationship between HLA antigens and infectious agents in contributing towards the development of Graves' disease. Immunol Invest. 1998;27:17-29.
392. Hammerstad SS, Jahnsen FL, Tauriainen S, et al. Inflam-mation and Increased Myxovirus Resistance Protein A Expression in Thyroid Tissue in the Early Stages of Hashimoto's Thyroiditis. Thyroid. 2013;23:334-341.
393. Blackard JT, Kong L, Huber AK, Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid. 2013; 23:863-870.
394. Vaccaro M, Guarneri F, Borgia F, Cannavo SP, Benvenga S. Association of lichen sclerosus and autoimmune thyroiditis: possible role of Borrelia burgdorferi? Thyroid. 2002;12:1147-1148.
395. Benvenga S, Guarneri F, Vaccaro M, Santarpia L, Trimarchi F. Homologies between proteins of Borrelia burgdorferi and thyroid autoantigens. Thyroid. 2004;14:964-966.
396. Benvenga S, Santarpia L, Trimarchi F, Guarneri F. Human thyroid autoantigens and proteins of Yersinia and Borrelia share amino acid sequence homology that includes binding motifs toHLA-DRmolecules and T-cell receptor. Thyroid. 2006;16:225-236.
397. Kamath C, Young S, Kabelis K, et al. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto's who developed Graves' disease and pretibial myxoedema. Clin Endocrinol (Oxf). 2012;77: 465-470.
398. Gregoric E, Gregoric JA, Guarneri F, Benvenga S. Injections of Clostridium botulinum neurotoxin A may cause thyroid complications in predisposed persons based on molecular mimicry with thyroid autoantigens. Endocrine. 2011;39:41-47.
399. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol. 2001;2:797-801.
400. Mangalam AK, Taneja V, David CS. HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. J Immunol. 2013;190:513-518.
401. von Herrath MG, Fujinami RS, Whitton JL. Microorganisms and autoimmunity: making the barren field fertile? Nat Rev Microbiol. 2003;1:151-157.
402. Di Genova G, Savelyeva N, Suchacki A, Thirdborough SM, Stevenson FK. Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid. Eur J Immunol. 2010;40: 976-985.
403. Kawashima A, Tanigawa K, Akama T, Yoshihara A, Ishii N, Suzuki K. Innate immune activation and thyroid autoimmunity. J Clin Endocrinol Metab. 2011;96: 3661-3671.
404. Enouz S, Carrié L, Merkler D, Bevan MJ, Zehn D. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J Exp Med. 2012;209:1769-1779.
405. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol. 2001;1:69-75.
406. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science. 2002;296: 490-494.
407. Cox SP, Phillips DI, Osmond C. Does infection initiate Graves disease? A population based 10 year study. Autoimmunity. 1989;4:43-49.